- Trump’s Executive Order on Drug Prices Might Be More in Favour of Drug Companies
- The Government Created This Zika Vaccine. Why Should Big Pharma Reap the Profits?
- In Thailand, patient activism is crucial to expanding treatment
- The Trump Executive Order on drug prices: not what was promised nor needed, and contrary to US self interest
- June 2017 Alert: Pressure on countries hiked by US on IP
Category Archives: Pre-grant opposition
The role of intellectual property in local production in developing countries: Opportunities and challenges
Source: World Health Organization Intellectual property plays an important role both for the researching pharmaceutical industry, which relies heavily on intellectual property to protect its products, and for generic companies, which produce copies of existing medicines once patent protection expires.
Hepatitis C patients in Malaysia urgently need access to affordable Sofosbuvir. Help them by signing this petition to the Health Minister of Malaysia in the run-up to the International Harm Reduction Conference in Kuala Lumpur.
MUMBAI, SEPT 15: Source: The Hindu California-based Gilead is set to stir the pot as it forges India-based alliances on its Hepatitis C drug sofosbuvir. Multi-company agreements on the drug are expected to be announced later today. Never before has … Continue reading
Gilead, local generic players in talks to bring hepatitis C drug into India PT JYOTHI DATTA Source:Hindu Business Line Price to be pegged lower than the current standard of care, estimated at $2,500 for six months MUMBAI, FEBRUARY 3: California-based … Continue reading
Press Release: Trade and Industry’s draft IP policy lays foundation to prevent abusive patents from blocking access to affordable medicines
Health groups call for wide public consultation Johannesburg, 9 September – The Treatment Action Campaign (TAC), Doctors Without Borders (MSF) and SECTION27 welcome the announcement that the Department of Trade and Industry (DTI) has called for public comment on the … Continue reading